ArticleCancer discovery2022

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.

Alison M Schram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.